Clinical trial of compound glycyrrhizin tablets in the treatment of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome
10.13699/j.cnki.1001-6821.2018.03.015
- VernacularTitle:复方甘草酸苷片治疗自身免疫性肝炎-原发性胆汁肝硬化重叠综合征的临床研究
- Author:
Xiang-Yan FENG
1
;
Zeng-Tao FENG
;
Yu-Zhuo MA
Author Information
1. 西安培华学院医学院
- Keywords:
compound glycyrrhizin tablet;
autoimmune hepatitis primary biliary cirrhosis overlap syndrome;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(3):240-243
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of compound glycyrrhizin tablets in the treatment of autoimmune hepatitis primary biliary cirrhosis with overlap syndrome (AIH-PBC).Methods Forty-six patients with AIH-PBC were randomly divided into control group and treatment group with 23 cases per group.Control group received 10 mg · kg-1ursodeoxycholic acid capsule,qd,orally + prednisone acetate tablet,orally,starting dose 0.5 mg · kg-1 · d-1,and gradually reduce to 5 mg · d-1 to maintain treatment + azathioprine tablets 50 mg · d-1,orally.Treatment group was given compound glycyrrhizin tablets 75 mg each time,tid,orally,on the basis of control group.Two groups were treated for 12 months.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were respectively 91.30％ (21 cases/23 cases) and 60.87％ (14 cases/23 cases) with significant difference (P ＜ 0.05).The adverse drug reactions of treatment group were diarrhea,gastrointestinal discomfort and headache,which in control group were diarrhea and gastrointestinal discomfort.The incidences of adverse drug reactions in treatment and control groups were 17.39％ and 26.09％ without significant difference (P ＞ 0.05).Conclusion Compound glycyrrhizin tablets have a definitive clinical efficacy in the treatment of AIH-PBC,without increasing the incidence of adverse drug reactions.
